Clinical trial results show that pembrolizumab, an immunotherapy drug used to treat multiple types of cancer, can dramatically improve outcomes for patients with colorectal cancer
United States agricultural hubs are currently facing an unprecedented outbreak of the H5N1 virus, more commonly known as the avian flu or “bird flu.” As
In the early days of the human immunodeficiency virus (HIV) epidemic, there was little hope. HIV infection, when untreated, damages the immune system, making people
Semaglutide, under the brand names Wegovy® and Ozempic®, has surged in popularity for its ability to help people lose weight and reduce the risk of
The Danish pharmaceutical company Novo Nordisk has announced promising early results for amycretin, a novel oral weight loss medication. This new drug appears to outperform
Death rates for cancer are lower than ever, having declined as much as 33 percent since 1991. This is largely thanks to innovations in oncology
The relationship between cancer and the nervous system has been a curiosity and mystery for nearly two centuries. Jean Cruveilhier’s initial observations in the early
NodThera, a biotech company based in Cambridge, England, is developing a new class of medicines that inhibit the NOD-, LRR- and pyrin domain-containing protein 3
Annual flu shots in the United States are going to be made a little differently this year, as one of the flu strains usually included
As GLP-1 receptor agonist injections continue to gain acceptance as effective solutions for weight management and cardiovascular health, a tiny drug-delivering implant from Vivani Medical
Traumatic brain injuries (TBIs), commonly experienced by military personnel, often incur deep damage and invisible scars. Such injuries are significant contributors to post-traumatic stress disorder
Glucagon-like peptide-1 (GLP-1) receptor agonists are arguably the hottest topic in medical innovation. The drugs semaglutide and tirzepatide, known under brand names like Ozempic, Wegovy,
Clinical trial results show that pembrolizumab, an immunotherapy drug used to treat multiple types of cancer, can dramatically improve outcomes for patients with colorectal cancer
United States agricultural hubs are currently facing an unprecedented outbreak of the H5N1 virus, more commonly known as the avian flu or “bird flu.” As
In the early days of the human immunodeficiency virus (HIV) epidemic, there was little hope. HIV infection, when untreated, damages the immune system, making people
Semaglutide, under the brand names Wegovy® and Ozempic®, has surged in popularity for its ability to help people lose weight and reduce the risk of
The Danish pharmaceutical company Novo Nordisk has announced promising early results for amycretin, a novel oral weight loss medication. This new drug appears to outperform
Death rates for cancer are lower than ever, having declined as much as 33 percent since 1991. This is largely thanks to innovations in oncology
The relationship between cancer and the nervous system has been a curiosity and mystery for nearly two centuries. Jean Cruveilhier’s initial observations in the early
NodThera, a biotech company based in Cambridge, England, is developing a new class of medicines that inhibit the NOD-, LRR- and pyrin domain-containing protein 3
Annual flu shots in the United States are going to be made a little differently this year, as one of the flu strains usually included
As GLP-1 receptor agonist injections continue to gain acceptance as effective solutions for weight management and cardiovascular health, a tiny drug-delivering implant from Vivani Medical
Traumatic brain injuries (TBIs), commonly experienced by military personnel, often incur deep damage and invisible scars. Such injuries are significant contributors to post-traumatic stress disorder
Glucagon-like peptide-1 (GLP-1) receptor agonists are arguably the hottest topic in medical innovation. The drugs semaglutide and tirzepatide, known under brand names like Ozempic, Wegovy,
Delaware Technology Park,
3 Innovation Way,
Newark, DE 19711
"*" indicates required fields
Emails are serviced by Constant Contact. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email.